ONC

BeiGene
D

ONC

Arincen62/100B

BeiGene income statement 2013–2026

6.61B USD over the last twelve months, and 5.34B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
6.61B5.34B3.81B2.46B1.42B1.18B308.87M428.21M198.22M238.39M1.07M
Revenue growth
+32.86%+40.23%+54.96%+73.65%+20.37%+280.83%-27.87%+116.03%-16.85%+22,179.16%-87.86%
Cost of revenue
701.06M668.54M594.09M379.92M286.48M164.91M70.66M71.19M707.71M273.99M98.03M
Gross profit
5.91B4.67B3.22B2.08B1.13B1.01B238.22M357.02M-509.49M-35.61M-96.96M
Gross margin
89.39%87.49%84.41%84.55%79.77%85.98%77.12%83.38%-257.03%-14.94%-9,061.96%
Research and development
2.43B2.15B1.95B1.78B1.64B1.46B1.29B927.34M679.01M269.02M98.03M
Selling, general and administrative
2.30B2.08B1.83B1.51B1.28B990.12M600.18M388.25M195.39M62.60M20.10M
Operating expenses
4.73B4.23B3.78B3.29B2.92B2.45B1.90B1.32B196.28M62.85M20.10M
1.18B447.14M-568.20M-1.21B-1.79B-1.44B-1.66B-959.89M-705.77M-98.46M-117.06M
Operating income growth
+545.22%——————————
Operating margin
17.84%8.37%-14.91%-49.12%-126.40%-122.31%-536.69%-224.16%-356.05%-41.30%-10,940.19%
Interest income
147.36M70.51M47.84M74.01M52.48M15.76M2.00M9.13M13.95M——
Interest expense
—58.23M———————4.11M383.00K
Other non-operating income
-47.38M-30.28M35.20M381.90M-171.37M147.00K39.49M16.31M15.94M7.39M-2.10M
Pretax income
1.13B416.85M-533.00M-825.84M-1.96B-1.44B-1.62B-943.59M-689.83M-91.06M-119.16M
Income tax
215.70M129.92M111.79M55.87M42.78M19.23M10.40M6.99M-15.80M2.24M54.00K
Effective tax rate
19.07%31.17%—————————
915.57M286.93M-644.79M-881.71M-2.00B-1.46B-1.62B-948.63M-673.77M-93.11M-119.22M
Net income growth
+1,235.63%——————————
Net margin
13.86%5.37%-16.92%-35.86%-141.52%-123.93%-526.10%-221.53%-339.91%-39.06%-11,141.78%
Basic shares
111.32M109.06M105.29M104.39M103.13M92.79M83.47M60.05M55.44M41.78M31.05M
Diluted shares
115.58M113.45M105.29M104.39M103.13M92.79M83.47M60.05M55.44M41.78M31.05M
Change in diluted shares
+3.94%+7.75%+0.86%+1.22%+11.15%+11.16%+38.99%+8.32%+32.69%+34.58%-1.49%
EPS (basic)
64.742.63-6.12-8.45-19.37-15.21-19.11-15.86-12.09-2.21-3.90
EPS (diluted)
62.012.53-6.12-8.45-19.37-15.21-19.11-15.86-12.09-2.21-3.90
EPS growth
+379.21%——————————
EBITDA
1.43B616.77M-361.24M-738.16M-1.89B-1.39B-1.63B-941.27M-695.38M-93.70M-115.15M
EBITDA margin
21.61%11.54%-9.48%-30.02%-133.82%-118.35%-526.39%-219.82%-350.81%-39.31%-10,761.78%
EBIT
1.31B475.09M-533.00M-825.84M-1.96B-1.44B-1.66B-959.89M-705.77M-98.46M-117.06M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about BeiGene's income statement

Source: Financial Modeling Prep